Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma-Reference-Cited by-同舟云学术

Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma

Published:2019-04-30 Issue: Volume:9 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Dréau Didier,Moore Laura Jeffords,Wu Mike,Roy Lopa Das,Dillion Lloye,Porter Travis,Puri Rahul,Momin Noor,Wittrup K. Dane,Mukherjee Pinku

Funder

National Institutes of Health

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference83 articles.

1. Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer;Bunt;Cancer Immunol Immunother.,2013

2. Cancer immunotherapy for pancreatic cancer utilizing alpha-gal epitope/natural anti-Gal antibody reaction;Tanemura;World J Gastroenterol.,2015

3. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy;Amedei;Hum Vaccines Immunother.,2014

4. Current and emerging targeting strategies for treatment of pancreatic cancer;Baines;Prog Mol Biol Transl Sci.,2016

5. Multimodal treatment of resectable pancreatic ductal adenocarcinoma;Silvestris;Crit Rev Oncol Hematol.,2017

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector;Journal of Microbiology;2024-05-03

2. Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression;Frontiers in Oncology;2024-04-18

3. Molecular crosstalk between MUC1 and STAT3 influences the anti-proliferative effect of Napabucasin in epithelial cancers;Scientific Reports;2024-02-07

4. Overexpression of MUC1 influences the anti-proliferative effect of STAT3-inhibitor Napabucasin in epithelial cancers;2023-06-25

5. Anti–PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression;Cancer Immunology Research;2023-03-15